Search

Your search keyword '"Brandi, M.L."' showing total 277 results
Start Over Author "Brandi, M.L."
277 results on '"Brandi, M.L."'

7. Does nutrition play a role in the prevention and management of sarcopenia?

Author

Al-Daghri, N., Allepaerts, S., Bauer, J., Brandi, M.L., Cederholm, T., Cherubini, A., Cruz Jentoft, A., Laviano, A., Maggi, S., McCloskey, E.V., Petermans, J., Roubenoff, R., Rueda, R., Robinson, S.M., Reginster, J.Y., Rizzoli, R., Shaw, S.C., Kanis, J.A., Bautmans, I., Bischoff-Ferrari, H., Bruyère, O., Cesari, M., Dawson-Hughes, B., Fielding, R.A., Kaufman, J.M., Landi, F., Malafarina, V., Rolland, Y., van Loon, L.J., Vellas, B., Visser, M., and Cooper, C.

Published
2018
Full Text
View/download PDF

8. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)

Author

Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., Brandi, M.L., Bruyère, O., Burlet, N., Cooper, C., Cortet, B., Dennison, E., Diez-Perez, A., Gasparik, A., Grosso, A., Hadji, P., Halbout, P., Kanis, J.A., Kaufman, J.M., Laslop, A., Maggi, S., Rizzoli, R., Thomas, T., Tuzun, S., Vlaskovska, M., and Reginster, J.Y.

Published
2019
Full Text
View/download PDF

11. Treatment of osteoporosis in men

Author

Kaufman, J.-M., Reginster, J.-Y., Boonen, S., Brandi, M.L., Cooper, C., Dere, W., Devogelaer, J.-P., Diez-Perez, A., Kanis, J.A., McCloskey, E., Mitlak, B., Orwoll, E., Ringe, J.D., Weryha, G., and Rizzoli, R.

Published
2013
Full Text
View/download PDF

12. Antidepressant medications and osteoporosis

Author

Rizzoli, R., Cooper, C., Reginster, J.-Y., Abrahamsen, B., Adachi, J.D., Brandi, M.L., Bruyère, O., Compston, J., Ducy, P., Ferrari, S., Harvey, N.C., Kanis, J.A., Karsenty, G., Laslop, A., Rabenda, V., and Vestergaard, P.

Published
2012
Full Text
View/download PDF

15. Contributors

Author

Abbasi, S., primary, Adolphi, N.L., additional, Aikawa, E., additional, Akbar, H., additional, Akilesh, S., additional, Aladjem, M.I., additional, Allocca, M., additional, Alpini, G., additional, Alroy, J., additional, Altman, B.J., additional, Andujar, P., additional, Antonello, Z.A., additional, Antsiferova, M., additional, Apica, B.S., additional, Ariel, I., additional, Aronow, B.J., additional, Ashley, J.W., additional, Badell, I.R., additional, Bagg, A., additional, Bajaj, M., additional, Banerjee, S., additional, Barbieri, J.S., additional, Bardes, E.E., additional, Barisoni, L., additional, Barletta, J.A., additional, Baskin, D.G., additional, Bastarrachea, R.A., additional, Bayat, A., additional, Bayrak-Toydemir, P., additional, Beck, A.H., additional, Beebe, D.C., additional, Beltran, H., additional, Benichou, G., additional, Bergman, M., additional, Bernard, S.A., additional, Bernardi, P., additional, Best, D.H., additional, Blair, H.C., additional, Bonaldo, P., additional, Bondy, J., additional, Bosman, F.T., additional, Bouma, B.E., additional, Brandi, M.L., additional, Bresler, S.C., additional, Brewer, M.T., additional, Britto, C.J., additional, Brock, J.E., additional, Brosens, L.A.A., additional, Budge, H., additional, Burd, E.M., additional, Burness, M.L., additional, Bushnell, T., additional, Byrd, J., additional, Calderone, A., additional, Campbell, M.J., additional, Cao, D., additional, Capell, W., additional, Cardigan, R., additional, Carey, P.M., additional, Carneiro, F., additional, Carp, S.A., additional, Carter, A.M., additional, Cascio, M.J., additional, Castellani, R.J., additional, Castellanos, J., additional, Caviglia, J.M., additional, Cecconi, F., additional, Chamarthy, S., additional, Chamma, E., additional, Chang, A., additional, Chang, A.Y., additional, Chang, N.C., additional, Chapman, D.G., additional, Charles, A.K., additional, Chen, D., additional, Chen, D.F., additional, Chen, P., additional, Cheng, J., additional, Chernock, R.D., additional, Cheruvu, S., additional, Chiang, J., additional, Childs, G.V., additional, Cho, Y.-B., additional, Choi, A.M.K., additional, Choi, J.K., additional, Cipriani, N.A., additional, Cleary, J.O.S.H., additional, Clementi, E., additional, Clines, G.A., additional, Cohen, M.L., additional, Coleman, W.B., additional, Coletta, D.K., additional, Collie, A.M.B., additional, Cooling, L., additional, Coron, E., additional, Côté, D., additional, Coussens, L.M., additional, Crielaard, B.J., additional, Cron, R.Q., additional, Crum, C.P., additional, Cruz, N.M., additional, Dairkee, S.H., additional, Daly, C.A., additional, Dang, C.V., additional, Danila, M.I., additional, Daradich, A., additional, Darnell, C.M., additional, Dartt, D.A., additional, Das, A., additional, D’Asta, F., additional, DeFronzo, R., additional, De Hertogh, G., additional, Dela Cruz, C.S., additional, de la Cruz-Merino, L., additional, De Palma, C., additional, Demetris, A.J., additional, DeMorrow, S., additional, Denechaud, P.-D., additional, Di Carli, M.F., additional, DiCarlo, E.F., additional, Dikic, I., additional, Dimberg, A., additional, Dowell, M.L., additional, Doyle, L.A., additional, Drachenberg, C.B., additional, Driskell, E., additional, Duda, D.G., additional, Duker, J., additional, Dyck, J.R.B., additional, Ecker, C., additional, Elifritz, J.M., additional, Elsheikh, T.M., additional, Ensari, A., additional, Ernst, L.M., additional, Esch, K.J., additional, Fajas-Coll, L., additional, Fang, Q., additional, Farhat, N.A., additional, Farshid, G., additional, Faye-Petersen, O.M., additional, Fehlings, M.G., additional, Fend, F., additional, Feng, X., additional, Fernandes, H., additional, Fernandez-Checa, J.C., additional, Ferreira, B.P., additional, Fidler, I.J., additional, Finn, J.A., additional, Fischer, A., additional, Fishbein, M.C., additional, Fleit, H.B., additional, Flomenbaum, M., additional, Folkins, A., additional, Francis, H., additional, Frank, K.M., additional, Frevert, C.W., additional, Frias, A.E., additional, Friedman, J.R., additional, Fukumura, D., additional, Furie, M.B., additional, Gaffo, A.L., additional, Galateau-Sallé, F., additional, Gallegos-Cabriales, E.C., additional, Gandhi, C.R., additional, Gannon, M., additional, García-Moliner, M.L., additional, Gardner, J.M., additional, Gasper, C.A., additional, Gaulard, P., additional, Gaut, J.P., additional, Gavia-García, G., additional, Gerrard, C., additional, Ghosh, A.P., additional, Giersch, A.B.S, additional, Gilbert, S.R., additional, Gill, J.R., additional, Giusti, F., additional, Glorioso, J.M., additional, González-Torres, M.C., additional, Goolsby, C.L., additional, Gora, M.J., additional, Gordon, I.O., additional, Gotlieb, A.I., additional, Gouw, A.M., additional, Goyal, A., additional, Grégoire, M., additional, Graham, B.B., additional, Granger, D.N., additional, Greene, A.K., additional, Greenlee, J.J., additional, Griffiths, R., additional, Guimarães, A.R., additional, Gulati, M., additional, Gullet, A., additional, Gupta, S., additional, Haider, N.B., additional, Halushka, M.K., additional, Hambuch, T.M., additional, Hamza, S.M., additional, Han, Y., additional, Hansen, W.P., additional, Hard, R., additional, Harris, B.T., additional, Harris, J.E., additional, Hartnett, M.E., additional, Hasserjian, R.P., additional, Hatch, G.M., additional, Hefti, M.M., additional, Heller, D.S., additional, Hemminger, J.A., additional, Hendrickson, J.E., additional, Henley, K.D., additional, Herzog, E., additional, Hess, J.R., additional, Hill, C.E., additional, Hipp, J., additional, Hobbs, R., additional, Höller, D., additional, Hodges, R.R., additional, Homer, R.J., additional, Horowitz, N., additional, Hsi, E.D., additional, Hsieh, A.L., additional, Hunt, J.M., additional, Hure, S., additional, Husain, A.N., additional, Hussey, S., additional, Hutcheson, J.D., additional, Hutson, R.M., additional, Illescas-Vacas, A., additional, Irvin, C.G., additional, Jaffer, F.A., additional, Jäger, R., additional, Jain, R.K., additional, Jain, S., additional, James, J., additional, Jansen, M., additional, Jarzembowski, J.A., additional, Jaurand, M.-C., additional, Jean, D., additional, Jegga, A.G., additional, Jellinger, K.A., additional, Jen, K.-Y., additional, Jo, V.Y., additional, Johnson, B., additional, Jones, R.L., additional, Kalfa, T.A., additional, Kamionek, M., additional, Kang, D., additional, Kantari, C., additional, Kantor, P.F., additional, Kanzaki, G., additional, Karns, R., additional, Katzman, P.J., additional, Kawai, T., additional, Kelley, T.W., additional, Kent, J.W., additional, Kerr, E.H., additional, Kew, R.R., additional, Khalighi, M., additional, Khanh Vu, T.H., additional, Khong, T.Y., additional, Kim, B.S., additional, Kim, J., additional, Klein, M.J., additional, Knechtle, S.J., additional, Konkle, B.A., additional, Kowalewska, J., additional, Kricka, L.J., additional, Krishnan, B., additional, Kumar, A., additional, Kumar, S., additional, Kvietys, P., additional, Kwong, R.Y., additional, Lafont, E., additional, Laga, A.C., additional, Lagarrigue, S., additional, Lakin, A., additional, Laszik, Z.G., additional, Lauwers, G.Y., additional, Laver, N.V., additional, Lawlor, M.W., additional, Lederer, J.A., additional, Lee, R.E., additional, Lee, W.M., additional, LeGallo, R., additional, Leich, E., additional, Lemmens, B., additional, Le Pimpec-Barthes, F., additional, Leval, L., additional, Levy, B.D., additional, Lewis, J.S., additional, Lewis, T.L., additional, Leyva-Illades, D., additional, Li, L., additional, Li, Y.-P., additional, Lianidou, E.S., additional, Liao, L., additional, Liapis, H., additional, Lin, J.B., additional, Lin, A.-L., additional, Lindsay, M.E., additional, Liu, E., additional, Longacre, T., additional, Lopez-Alvarenga, J.C., additional, Lopez-Mejía, I., additional, Lozanski, G., additional, Lucia, M.S., additional, Luk, E., additional, Lutty, G.A., additional, Maclellan, R.A., additional, Madabhushi, A., additional, Mahindra, A., additional, Malek, E., additional, Mammucari, C., additional, Mani, H., additional, Mao, S.A., additional, Marboe, C.C., additional, Marí, M., additional, Marini, F., additional, Markou, A., additional, Marshall, A.H., additional, Martin, S.J., additional, Marzioni, M., additional, Masli, S., additional, Matsukuma, K.E., additional, Matulonis, U.A., additional, Mayfield, J., additional, McCoy, J.P., additional, McDougle, C.J., additional, McGinnis, M.R., additional, McGuire, A., additional, McKinstry, K.K., additional, McManus, B.M., additional, Means, A.L., additional, Meny, G.M., additional, Merchant, N., additional, Meserve, E.E.K, additional, Mess, A.M., additional, Minervini, M.I., additional, Mitchell, R.N., additional, Monaco, S.E., additional, Monga, S.P., additional, Monica Way, H.-Y., additional, Montecucco, C., additional, Montone, K.T., additional, Morgan, E.A., additional, Morgan, T.K., additional, Morrissey, K., additional, Mortensen, R.M., additional, Moser, S.A., additional, Mosquera, J.M., additional, Mossman, B.T., additional, Motta, A.C.F., additional, Mullins, E., additional, Murphy, G.F., additional, Murray, L., additional, Mysorekar, I.U., additional, Nadel, B., additional, Nadon, A.S., additional, Nagathihalli, N., additional, Nájera-Medina, O., additional, Nalesnik, M.A., additional, Nast, C.C., additional, Natkunam, Y., additional, Nault, J.C., additional, Nava-González, E.J., additional, Nayar, R., additional, Nerenz, R.D., additional, Neumann, H., additional, Ni, H., additional, Nolte, K.B., additional, Norton, L., additional, Nowak, J., additional, Nucera, C., additional, Nyberg, S.L., additional, Oakes, S.A., additional, Offerhaus, G.J.A., additional, Ojha, S., additional, Okabe, H., additional, Oliveira, A.M., additional, Osborn, E.A., additional, O'Tierney-Ginn, P., additional, Ott, G., additional, Ozcan, A., additional, Padera, R.F., additional, Pagano, M.B., additional, Page, E.K., additional, Paintal, A.S., additional, Pairon, J.-C., additional, Papadimitriou, J.C., additional, Park, H.-J., additional, Park, J.Y., additional, Parsons, L.N., additional, Patra, D., additional, Peclovits, A., additional, Peeters, P.M., additional, Perkins, T.N., additional, Perry, G., additional, Perumbeti, A., additional, Petersen, C.A., additional, Petrache, I., additional, Petroff, M.G., additional, Pettus, J.R., additional, Picken, M.M., additional, Pierson, C.R., additional, Pittman, M.E., additional, Pogoriler, J., additional, Politi, K., additional, Pollack, S.M., additional, Quintanilla-Martínez, L., additional, Rai, M.F., additional, Ramkissoon, S., additional, Randhawa, P.S., additional, Rangel, J.R., additional, Rasola, A., additional, Reeves, B., additional, Reheman, A., additional, Remick, D.G., additional, Reynaert, N.L., additional, Richmond, J.M., additional, Rivella, S., additional, Rivenbark, A.G., additional, Rizzuto, R., additional, Roberts, K.A., additional, Robin, D.A., additional, Robinson, L.J., additional, Rockey, D.C., additional, Rosenwald, A., additional, Rossetto, O., additional, Roth, K.A., additional, Roy-Chowdhury, J., additional, Roy-Chowdhury, N., additional, Rubin, M.A., additional, Rudnicki, M.A., additional, Russell, D.S., additional, Ryter, S.W., additional, Saban, D.R., additional, Sacher, R.A., additional, Sacks, D.B., additional, Sagaert, X., additional, Sagdeo, A., additional, Sahay, B., additional, Sahin, A., additional, Samali, A., additional, Sampson, B., additional, Sánchez-Escribano, R., additional, Sandri, M., additional, Sanyal, A., additional, Sasatomi, E., additional, Sauer, V., additional, Scherpereel, A., additional, Schmidt, E.P., additional, Schwabe, R.F., additional, Scorrano, L., additional, Scott, M.G., additional, Scull, J.C., additional, Seidman, M.A., additional, Seki, A., additional, Sellati, T.J., additional, Serban, K., additional, Serhan, C.N., additional, Seshan, S.V., additional, Seth, A., additional, Seykora, J.T., additional, Sharma, N., additional, Shi, C., additional, Shi, S.-R., additional, Shimada, M., additional, Shimizu, A., additional, Singer, D.B., additional, Sitko, K., additional, Smallwood, R.F., additional, Smiraglia, D.J., additional, Smith, B.R., additional, Smola, H., additional, Soubeyrand, M., additional, Stahl, W.L., additional, Stajić, M., additional, Stanworth, S.J., additional, Stathatos, N., additional, Stemler, K.M., additional, Stevens, T.M., additional, Stine, Z.E., additional, Stoll, M.L., additional, Strati, A., additional, Strutt, T.M., additional, Sund, M., additional, Sung, M.M., additional, Symonds, M.E., additional, Tabar, S., additional, Takahashi, N., additional, Talmadge, J.E., additional, Tang, V., additional, Tangrea, M., additional, Tarango, C., additional, Tario, J.D., additional, Taylor, C.R., additional, Taylor, R., additional, Tearney, G.J., additional, Tefera, K., additional, Thomas, S., additional, Thornburg, K.L., additional, Tirado, C.A., additional, Tobian, A.A.R., additional, Tomaszewski, J.E., additional, Tormey, C.A., additional, Torres, R., additional, Tran, M.-H., additional, Tredget, E.E., additional, Treister, N.S., additional, Trotter, J., additional, Troyer, D., additional, Truong, L., additional, Tubbs, R.R., additional, Turakhia, S., additional, Unglert, C.I., additional, Utheim, T., additional, Vahabzadeh, A., additional, van Bokhoven, A., additional, Vanden Berghe, T., additional, Vandenabeele, P., additional, van der Klei, I.J., additional, Vanguri, V.K., additional, Van Noorden, C.J.F, additional, Van Poznak, C., additional, Vassallo, R.R., additional, Vawda, R., additional, Vieth, M., additional, Visscher, D.W., additional, Volk, S.W., additional, Vyas, G.N., additional, Waggoner, S.N., additional, Walczak, H., additional, Walker, D.H., additional, Wallace, P.K., additional, Wanat, K.A., additional, Wang, J., additional, Wang, Y., additional, Wang, Y.X., additional, Warger, W.C., additional, Wei, S., additional, Weinman, S.A., additional, Wenig, B.M., additional, Wentz, S.C., additional, Werner, S., additional, Wertheim, G., additional, Whitley, E.M., additional, Wooderchak-Donahue, W., additional, Woods, K., additional, Wouters, E.F.M., additional, Wu, Y., additional, Xing, W., additional, Yachimski, P., additional, Yan, P., additional, Yang, J., additional, Yang, L., additional, Yoshizawa, S., additional, Yuan, J., additional, Yun, S.-H., additional, Yvon, A., additional, Zhang, H., additional, Zhang, P., additional, Zhao, Z., additional, Zhu, G., additional, Zhu, R., additional, Zordoky, B.N., additional, Zou, J., additional, Zuccato, J.A., additional, and Zucman-Rossi, J., additional

Published
2014
Full Text
View/download PDF

16. Paget’s Disease

Author

Giusti, F., primary, D’Asta, F., additional, Marini, F., additional, and Brandi, M.L., additional

Published
2014
Full Text
View/download PDF

17. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

Author

Kendler, David, Body, Jean-Jacques, Brandi, M.L., Broady, Raewyn, Cannata-Andía, Jorge J.B., Cannata-Ortiz, Jimena M.J., El Maghraoui, Abdellah, Guglielmi, Giuseppe, Hadji, Peyman, Pierroz, Dominique, De Villiers, Tobie, Ebeling, Peter R, Rizzoli, René, Kendler, David, Body, Jean-Jacques, Brandi, M.L., Broady, Raewyn, Cannata-Andía, Jorge J.B., Cannata-Ortiz, Jimena M.J., El Maghraoui, Abdellah, Guglielmi, Giuseppe, Hadji, Peyman, Pierroz, Dominique, De Villiers, Tobie, Ebeling, Peter R, and Rizzoli, René

Abstract

Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT. Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture. Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2021

19. Alternative and complementary therapies in osteoarthritis and cartilage repair

Author

Fuggle, Nicholas, Cooper, Cyrus, Oreffo, Richard, Price, A.J., Kaux, J.F., Maheu, E., Cutolo, M., Honvo, G., Conaghan, P.G., Berenbaum, F., Branco, J., Brandi, M.L., Cortet, B., Veronese, N., Kurth, A.A., Matijevic, R., Roth, R., Pelletier, J.P., Martel-Pelletier, J., Vlaskovska, M., Thomas, T., Lems, W.F., Al-Daghri, N., Bruyere, O., Rizzoli, R., Kanis, J.A., and Reginster, J.Y.

Abstract

Osteoarthritis (OA) is the most common joint condition and, with a burgeoning ageing population, is due to increase in prevalence. Beyond conventional medical and surgical interventions, there are an increasing number of ‘alternative’ therapies. These alternative therapies may have a limited evidence base and, for this reason, are often only afforded brief reference (or completely excluded) from current OA guidelines. Thus, the aim of this review was to synthesize the current evidence regarding autologous chondrocyte implantation (ACI), mesenchymal stem cell (MSC) therapy, platelet-rich plasma (PRP), vitamin D and other alternative therapies. The majority of studies were in knee OA or chondral defects. Matrix-assisted ACI has demonstrated exceedingly limited, symptomatic improvements in the treatment of cartilage defects of the knee and is not supported for the treatment of knee OA. There is some evidence to suggest symptomatic improvement with MSC injection in knee OA, with the suggestion of minimal structural improvement demonstrated on MRI and there are positive signals that PRP may also lead to symptomatic improvement, though variation in preparation makes inter-study comparison difficult. There is variability in findings with vitamin D supplementation in OA, and the only recommendation which can be made, at this time, is for replacement when vitamin D is deplete. Other alternative therapies reviewed have some evidence (though from small, poor-quality studies) to support improvement in symptoms and again there is often a wide variation in dosage and regimens. For all these therapeutic modalities, although controlled studies have been undertaken to evaluate effectiveness in OA, these have often been of small size, limited statistical power, uncertain blindness and using various methodologies. These deficiencies must leave the question as to whether they have been validated as effective therapies in OA (or chondral defects). The conclusions of this review are that all alternative interventions definitely require clinical trials with robust methodology, to assess their efficacy and safety in the treatment of OA beyond contextual and placebo effects.

Published
2020

21. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters

Author

van Beek, D.-J. (Dirk-Jan), Nell, S. (Sjoerd), Verkooijen, H.M. (Helena M.), Borel Rinkes, I.H.M. (Inne), Valk, G.D. (Gerlof), Vriens, M.R. (Menno), Goudet, P. (Pierre), Santucci, N. (Nicolas), Bartsch, D.K. (Detlef), Manoharan, J. (Jerena), Perrier, N.D. (Nancy D.), Zagzag, J. (Jonathan), Brandi, M.L., Giusti, F. (Francesca), Nilubol, N. (Naris), Brunaud, L. (Laurent), Pasternak, J.D. (Jesse D.), Hsiao, R. (Ralph), Sturgeon, C. (Cord), Giri, S. (Sneha), Conemans, E.B. (Elfi B.), Brosens, L.A. (Lodewijk), Bonsing, B.A. (Bert), Eijck, C.H.J. (Casper) van, Goor, H. (Harry) van, Kleine, R.H.J. (Ruben) de, Nieveen Van Dijkum, E.J.M. (Els), Kazemier, G. (Geert), Dejong, C.H. (Cees), van Beek, D.-J. (Dirk-Jan), Nell, S. (Sjoerd), Verkooijen, H.M. (Helena M.), Borel Rinkes, I.H.M. (Inne), Valk, G.D. (Gerlof), Vriens, M.R. (Menno), Goudet, P. (Pierre), Santucci, N. (Nicolas), Bartsch, D.K. (Detlef), Manoharan, J. (Jerena), Perrier, N.D. (Nancy D.), Zagzag, J. (Jonathan), Brandi, M.L., Giusti, F. (Francesca), Nilubol, N. (Naris), Brunaud, L. (Laurent), Pasternak, J.D. (Jesse D.), Hsiao, R. (Ralph), Sturgeon, C. (Cord), Giri, S. (Sneha), Conemans, E.B. (Elfi B.), Brosens, L.A. (Lodewijk), Bonsing, B.A. (Bert), Eijck, C.H.J. (Casper) van, Goor, H. (Harry) van, Kleine, R.H.J. (Ruben) de, Nieveen Van Dijkum, E.J.M. (Els), Kazemier, G. (Geert), and Dejong, C.H. (Cees)

Abstract

Background: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related insulinomas and assessed factors associated with prognosis. Methods: Patients who underwent resection of a multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors between 1990 and 2016 were identified in 2 databases: the DutchMEN Study Group and the International MEN1 Insulinoma Study Group databases. Cox regression was performed to compare liver metastases-free survival of patients with a nonfunctioning pancreatic neuroendocrine tumors versus those with an insulinoma and to identify factors associated with liver metastases-free survival. Results: Out of 153 patients with multiple endocrine neoplasia type 1, 61 underwent resection for a nonfunctioning pancreatic neuroendocrine tumor and 92 for an insulinoma. Of the patients with resected lymph nodes, 56% (18/32) of nonfunctioning pancreatic neuroendocrine tumors had lymph node metastases compared to 10% (4/41) of insulinomas (P = .001). Estimated 10-year liver metastases-free survival was 63% (95% confidence interval 42%–76%) for nonfunctioning pancreatic neuroendocrine tumors and 87% (72%–91%) for insulinomas. After adjustment for size, World Health Organization tumor grade, and age, nonfunctioning pancreatic neuroendocrine tumors had an increased risk for liver metastases or death (hazard ratio 3.04 [1.47–6.30]). In pancreatic neuroendocrine tumors ≥2 cm, nonfunctioning pancreatic neuroendocrine tumors (2.99 [1.22–7.33]) and World Health Organization grade 2 (2.95 [1.02–8.50]) were associated with liver metast

Published
2020
Full Text
View/download PDF

22. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs

Author

Fuggle, Nicholas N.R., Cooper, Cyrus, Harvey, Nicholas N.C., Al-Daghri, Nasser, Brandi, M.L., Bruyère, Olivier, Cano, Antonio, Dennison, Elaine E.M., Diez-Perez, Adolfo Diez A., Kaufman, Jean Marc, Palacios, Santiago, Prieto-Alhambra, Daniel, Rozenberg, Serge, Thomas, Thierry Y.P.Y., Trémollieres, Florence, Rizzoli, René, Kanis, John Anthony, Reginster, Jean-Yves, Fuggle, Nicholas N.R., Cooper, Cyrus, Harvey, Nicholas N.C., Al-Daghri, Nasser, Brandi, M.L., Bruyère, Olivier, Cano, Antonio, Dennison, Elaine E.M., Diez-Perez, Adolfo Diez A., Kaufman, Jean Marc, Palacios, Santiago, Prieto-Alhambra, Daniel, Rozenberg, Serge, Thomas, Thierry Y.P.Y., Trémollieres, Florence, Rizzoli, René, Kanis, John Anthony, and Reginster, Jean-Yves

Abstract

The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications of osteoporosis medications. These are presented in this narrative review. Calcium supplementation could theoretically cause atheroma formation via calcium deposition, and in one study was found to be associated with myocardial infarction, but this has not been replicated. Vitamin D supplementation has been extensively investigated for cardiac benefit, but no consistent effect has been found. Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). Bisphosphonates could theoretically provide protection against atheroma. However, data from randomised trials and observational studies have neither robustly supported this nor consistently demonstrated the potential association with atrial fibrillation. Denosumab does not appear to be associated with cardiovascular disease and, although parathyroid hormone analogues are associated with palpitations and dizziness, no association with a defined cardiovascular pathology has been demonstrated. Finally, romosozumab has been shown to have a possible cardiovascular signal, and therefore post-market surveillance of this therapy will be vital., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2020

23. Phytoestrogens and Colon Cancer

Author

Pampaloni, B., primary, Mavilia, C., additional, Bartolini, E., additional, Tonelli, F., additional, Brandi, M.L., additional, and DAst, Federica, additional

Published
2013
Full Text
View/download PDF

26. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium (vol 14, 139, 2019)

Author

Javaid, M.K., Boyce, A., Appelman-Dijkstra, N., Ong, J., Defabianis, P., Offiah, A., Arundel, P., Shaw, N., Pos, V. dal, Underhil, A., Portero, D., Heral, L., Heegaard, A.M., Masi, L., Monsell, F., Stanton, R., Dijkstra, P.D.S., Brandi, M.L., Chapurlat, R., Hamdy, N.A.T., and Collins, M.T.

Published
2019
Full Text
View/download PDF

28. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms

Author

Brandi, M.L., Hukkanen, M., Umeda, T., Moradi-Bidhendi, N., Bianchi, S., Gross, S.S., Polak, J.M., and MacIntyre, I.

Subjects
Bones -- Growth, Nitric oxide -- Physiological aspects, Immunocytochemistry -- Analysis, Science and technology
Abstract

Immunocytochemistry and Northern blotting during bidirectional regulation of osteoclasts function by nitric oxide, shows the presence of the constitutive calcium-sensitive nitric oxide synthase (cNOS) isoform in normal rat osteoclasts, and in human preosteoclast cell line. The presence of inducible (I) NOS isoform was also demonstrated. A basal level of transcript was observed in human preosteoclast line. Osteoclasts function may require continuous increases in NO production by cNOS against a basal inhibitory background activity of the iNOS isoform.

Published
1995

29. The Authors reply: 'Dual energy X-ray absorptiometry: gold standard for muscle mass?'

Author

Buckinx, F., Landi, F., Cesari, M., Fieding, R.A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N.M., Allepaerts, S., Bauer, J., Bautmans, I., Brandi, M.L., Bruyere, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., McCloskey, E., Dawson-Hughes, B., Kaufman, J.-M., Laslop, A., Petermans, J., Reginster, J.-Y., Rizzoli, R., Robinson, S., Rolland, Y., Rueda, R., Vellas, B., and Kanis, J.A.

Published
2018

30. Pitfalls in the measurement of muscle mass: a need for a reference standard

Author

Buckinx, F., Landi, F., Cesari, M., Fielding, R.A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N.M., Allepaerts, S., Bauer, J., Bautmans, I., Brandi, M.L., Bruyere, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., McCloskey, E., Dawson-Hughes, B., Kaufman, J.-M., Laslop, A., Petermans, J., Reginster, J.-Y., Rizzoli, R., Robinson, S., Rolland, Y., Rueda, R., Vellas, B., Kanis, J.A., Internal medicine, APH - Aging & Later Life, APH - Health Behaviors & Chronic Diseases, AGEM - Endocrinology, metabolism and nutrition, Nutrition and Health, Gerontology, Frailty in Ageing, Research in Geriatrics and Gerontology, and Physical Medicine and Rehabilitation

Subjects
Sarcopenia, BODY-COMPOSITION, lcsh:Diseases of the musculoskeletal system, CELL LUNG-CANCER, Lean body mass, Lean mass, Muscle mass, Reference standard, Biophysics, Applied Microbiology and Biotechnology, Orthopedics and Sports Medicine, Physiology (medical), lcsh:QM1-695, ELECTRICAL-IMPEDANCE MYOGRAPHY, Bone Density, Medicine and Health Sciences, Humans, SEROLOGICAL BIOMARKERS, ddc:616, Settore MED/09 - MEDICINA INTERNA, IN-VIVO PRECISION, X-RAY ABSORPTIOMETRY, lcsh:Human anatomy, Reference Standards, BIOIMPEDANCE ANALYSIS, BIOELECTRICAL-IMPEDANCE, SKELETAL-MUSCLE, lcsh:RC925-935, PHYSICAL-DISABILITY
Abstract

Background\ud All proposed definitions of sarcopenia include the measurement of muscle mass, but the techniques and threshold values used vary. Indeed, the literature does not establish consensus on the best technique for measuring lean body mass. Thus, the objective measurement of sarcopenia is hampered by limitations intrinsic to assessment tools. The aim of this study was to review the methods to assess muscle mass and to reach consensus on the development of a reference standard.\ud \ud Methods\ud Literature reviews were performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis working group on frailty and sarcopenia. Face‐to‐face meetings were organized for the whole group to make amendments and discuss further recommendations.\ud \ud Results\ud A wide range of techniques can be used to assess muscle mass. Cost, availability, and ease of use can determine whether the techniques are better suited to clinical practice or are more useful for research. No one technique subserves all requirements but dual energy X‐ray absorptiometry could be considered as a reference standard (but not a gold standard) for measuring muscle lean body mass.\ud \ud Conclusions\ud Based on the feasibility, accuracy, safety, and low cost, dual energy X‐ray absorptiometry can be considered as the reference standard for measuring muscle mass.

Published
2018
Full Text
View/download PDF

34. Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services.

Author

Lems, W. F., Paccou, J., Zhang, J., Fuggle, N. R., Chandran, M., Harvey, N. C., Cooper, C., Javaid, K., Ferrari, S., Akesson, K. E., International Osteoporosis Foundation Fracture Working Group, Akesson, K.E., Brandi, M.L., Chevalley, T., Fardellone, P., Goemaere, S., Harvey, N.C., Holzer, G., Javaid, M.K., and Lems, W.

Subjects
DIAGNOSIS of bone fractures, BONE fracture prevention, PHOTON absorptiometry, AGE distribution, RISK assessment, OSTEOPOROSIS, SPINAL injuries, BONE density, BONE fractures, DISEASE risk factors
Abstract

Summary: Vertebral fractures are independent risk factors for vertebral and nonvertebral fractures. Since vertebral fractures are often missed, the relatively new introduction of vertebral fracture assessment (VFA) for imaging of the lateral spine during DXA-measurement of the spine and hips may contribute to detect vertebral fractures. We advocate performing a VFA in all patients with a recent fracture visiting a fracture liaison service (FLS). Fracture liaison services (FLS) are important service models for delivering secondary fracture prevention for older adults presenting with a fragility fracture. While commonly age, clinical risk factors (including fracture site and number of prior fracture) and BMD play a crucial role in determining fracture risk and indications for treatment with antiosteoporosis medications, prevalent vertebral fractures usually remain undetected. However, vertebral fractures are important independent risk factors for future vertebral and nonvertebral fractures. A development of the DXA technology, vertebral fracture assessment (VFA), allows for assessment of the lateral spine during the regular DXA bone mineral density measurement of the lumbar spine and hips. Recent approaches to the stratification of antiosteoporosis medication type according to baseline fracture risk, and differences by age in the indication for treatment by prior fracture mean that additional information from VFA may influence initiation and type of treatment. Furthermore, knowledge of baseline vertebral fractures allows reliable definition of incident vertebral fracture events during treatment, which may modify the approach to therapy. In this manuscript, we will discuss the epidemiology and clinical significance of vertebral fractures, the different methods of detecting vertebral fractures, and the rationale for, and implications of, use of VFA routinely in FLS. Summary points: • Vertebral fracture assessment is a tool available on modern DXA instruments and has proven ability to detect vertebral fractures, the majority of which occur without a fall and without the signs and symptoms of an acute fracture. • Most osteoporosis guidelines internationally suggest that treatment with antiosteoporosis medications should be considered for older individuals (e.g., 65 years +) with a recent low trauma fracture without the need for DXA. • Younger individuals postfracture may be risk-assessed on the basis of FRAX® probability including DXA and associated treatment thresholds. • Future fracture risk is markedly influenced by both site, number, severity, and recency of prior fracture; awareness of baseline vertebral fractures facilitates definition of true incident vertebral fracture events occurring during antiosteoporosis treatment. • Detection of previously clinically silent vertebral fractures, defining site of prior fracture, might alter treatment decisions in younger or older FLS patients, consistent with recent IOF-ESCEO guidance on baseline-risk-stratified therapy, and provides a reliable baseline from which to define new, potentially therapy-altering, vertebral fracture events. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study

Author

Nell, S., Goudet, P., Vella, A., Bartsch, D., Perrier, N., Sturgeon, C., Brunaud, B., Kebebew, E., Brandi, M.L., Zarnegar, R., Pasternak, J., Verkooijen, H. M., Borel Rinkes, I.H.M., Valk, G. D., Vriens, Mr, University Medical Center [Utrecht], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Mayo Clinic [Rochester], Philipps Universität Marburg, The University of Texas M.D. Anderson Cancer Center [Houston], Northwestern University [Chicago, Ill. USA], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Lorraine (UL), National Institutes of Health [Bethesda] (NIH), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Weill Medical College of Cornell University [New York], University Health Network, and université de Bourgogne, LNC

Subjects
[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, men1, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

38. Relaxin influences the growth of MCF-7 breast cancer cells: mitogenic and antimitogenic action depends on peptide concentration

Author

Bigazzi, M., Brandi, M.L., Bani, G., and Sacchi, T. Bani

Subjects
Relaxin -- Physiological aspects, Breast cancer -- Physiological aspects, Cell lines, Adenocarcinoma -- Physiological aspects, Health
Abstract

Background. The effects of relaxin (RLX) on the human breast adenocarcinoma cell line MCF-7 have been evaluated. Methods. The cells were maintained in culture with Dulbecco's modified Eagle's medium with 1% and 10% fetal calf serum. Highly purified porcine RLX was added at concentrations ranging between [10.sup.-11] and [10.sup.-6] M, and, after 96-hour incubation in the presence of the peptide, cell proliferation, intracellular cyclic adenosine monophosphate (cAMP) content, percent cycling cells, and structural and ultrastructural pattern were studied. Results. The results indicate that RLX is a direct modulator of MCF-7 cell proliferation, stimulating growth at low concentrations and inhibiting growth at high concentrations. Determinations of percent cycling cells and intracellular cAMP accumulation agree with the results of the growth studies. Addition of different concentrations of 8-Br-cAMP to the culture medium results in a dose-related stimulation of MCF-7 cell proliferation. Morphologic examination shows that, in the current experiments, RLX does not induce any clear-out signs of differentiation of MCF-7 cells in terms of activation of secretion or intracellular lipid deposition. Conclusion. These findings indicate that RLX should be regarded as a novel agent involved in the control of growth of human breast cancer cells. Cancer 1992; 70:639-643.

Published
1992

41. Does nutrition play a role in the prevention and management of sarcopenia?

Author

Robinson, S.M., primary, Reginster, J.Y., additional, Rizzoli, R., additional, Shaw, S.C., additional, Kanis, J.A., additional, Bautmans, I., additional, Bischoff-Ferrari, H., additional, Bruyère, O., additional, Cesari, M., additional, Dawson-Hughes, B., additional, Fielding, R.A., additional, Kaufman, J.M., additional, Landi, F., additional, Malafarina, V., additional, Rolland, Y., additional, van Loon, L.J., additional, Vellas, B., additional, Visser, M., additional, Cooper, C., additional, Al-Daghri, N., additional, Allepaerts, S., additional, Bauer, J., additional, Brandi, M.L., additional, Cederholm, T., additional, Cherubini, A., additional, Cruz Jentoft, A., additional, Laviano, A., additional, Maggi, S., additional, McCloskey, E.V., additional, Petermans, J., additional, Roubenoff, R., additional, and Rueda, R., additional

Published
2018
Full Text
View/download PDF

42. FRI0574 Radiofrequency echographic multi spectrometry (REMS) for the non-ionising diagnosis of osteoporosis at femoral neck: results of a multicenter clinical study comparing rems and dxa

Author

Cavalli, L., primary, Arioli, G., additional, Bianchi, G., additional, Caffarelli, C., additional, Matucci Cerinic, M., additional, Cianferotti, L., additional, Conversano, F., additional, Di Paola, M., additional, Gatti, D., additional, Girasole, G., additional, Giusti, A., additional, Gonnelli, S., additional, Manfredini, M., additional, Muratore, M., additional, Nuti, R., additional, Pisani, P., additional, Quarta, E., additional, Rossini, M., additional, Viapiana, O., additional, and Brandi, M.L., additional

Published
2018
Full Text
View/download PDF

46. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

Author

Diez-Perez, A. (Adolfo), Naylor, K.E., Abrahamsen, B., Agnusdei, D., Brandi, M.L., Cooper, C. (Charles), Dennison, E.M. (Elaine), Eriksen, E.F., Gold, D.T., Guañabens, N., Hadji, P. (Peyman), Hiligsmann, M. (Mickael), Horne, R., Josse, R., Kanis, J.A. (John), Obermayer-Pietsch, B. (Barbara), Prieto-Alhambra, D., Reginster, J-Y. (Jean-Yves), Rizzoli, R., Silverman, S. (Stuart), Zillikens, M.C. (Carola), Eastell, R. (Richard), Diez-Perez, A. (Adolfo), Naylor, K.E., Abrahamsen, B., Agnusdei, D., Brandi, M.L., Cooper, C. (Charles), Dennison, E.M. (Elaine), Eriksen, E.F., Gold, D.T., Guañabens, N., Hadji, P. (Peyman), Hiligsmann, M. (Mickael), Horne, R., Josse, R., Kanis, J.A. (John), Obermayer-Pietsch, B. (Barbara), Prieto-Alhambra, D., Reginster, J-Y. (Jean-Yves), Rizzoli, R., Silverman, S. (Stuart), Zillikens, M.C. (Carola), and Eastell, R. (Richard)

Abstract

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. Introduction: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. Methods: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. Results: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and

Published
2017
Full Text
View/download PDF

48. Taxonomy of rare genetic metabolic bone disorders (vol 26, pg 2529, 2015)

Author

Masi, L., Agnusdei, D., Bilezikian, J., Chappard, D., Chapurlat, R., Cianferotti, L., Devolgelaer, J.P., Maghraoui, A. el, Ferrari, S., Javaid, K., Kaufman, J.M., Liberman, U.A., Lyritis, G., Miller, P., Napoli, N., Roldan, E., Papapoulos, S., Watts, N.B., and Brandi, M.L.

Published
2015

50. Taxonomy of rare congenital metabolic bone disorders

Author

Masi, L., Agnusdei, D., Bilezikian, J., Chappard, Daniel, Chapurlat, R., Cianferotti, L., Devolgelaer, J.-P., El Maghraoui, A., Ferrari, S., Jakob, F., Javaid, K., Kaufman, J.-M., Liberman, U., Lyritis, G., Miller, P., Napoli, N., Roldan, E., Papapoulos, S., Watts, N.B., Brandi, M.L., Groupe d'Études Remodelage Osseux et bioMatériaux (GEROM), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; SummaryThis article reports a taxonomic classification of rare skeletal diseases based on metabolic phenotypes. It was prepared by The Skeletal Rare Diseases Working Group of the International Osteoporosis Foundation (IOF) and includes 116 OMIM phenotypes with 86 affected genes.IntroductionRare skeletal metabolic diseases comprise a group of diseases commonly associated with severe clinical consequences. In recent years, the description of the clinical phenotypes and radiographic features of several genetic bone disorders was paralleled by the discovery of key molecular pathways involved in the regulation of bone and mineral metabolism. Including this information in the description and classification of rare skeletal diseases may improve the recognition and management of affected patients.MethodsIOF recognized this need and formed a Skeletal Rare Diseases Working Group (SRD-WG) of basic and clinical scientists who developed a taxonomy of rare skeletal diseases based on their metabolic pathogenesis.ResultsThis taxonomy of rare genetic metabolic bone disorders (RGMBDs) comprises 116 OMIM phenotypes, with 86 affected genes related to bone and mineral homeostasis. The diseases were divided into four major groups, namely, disorders due to altered osteoclast, osteoblast, or osteocyte activity; disorders due to altered bone matrix proteins; disorders due to altered bone microenvironmental regulators; and disorders due to deranged calciotropic hormonal activity.ConclusionsThis article provides the first comprehensive taxonomy of rare metabolic skeletal diseases based on deranged metabolic activity. This classification will help in the development of common and shared diagnostic and therapeutic pathways for these patients and also in the creation of international registries of rare skeletal diseases, the first step for the development of genetic tests based on next generation sequencing and for performing large intervention trials to assess efficacy of orphan drugs.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results